Baccharis trimera aqueous extract modulates inflammation and nociception in mice

• Autor(a) principal: Natiely Silveira de Almeida
• Data de Publicação: 2021
• Outros Autores: Alexandre de Barros Falcão Ferraz, Cláudia Pedron, Dione Silva Corrêa, Luciene Bruno Vieira, Flavia Tasmim Techera Antunes, Alessandra Hubner de Souza
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Institucional da UFMG
• Texto Completo: https://doi.org/10.1186/s40816-021-00309-w; http://hdl.handle.net/1843/56259; https://orcid.org/0000-0003-2665-5200; https://orcid.org/0000-0003-4876-8302; https://orcid.org/0000-0002-3496-6749; https://orcid.org/0000-0003-0620-2984; https://orcid.org/0000-0002-6832-2765
• topic: Anti-inflammatory effect; Antioxidant assay; Flavonoids; Phenolic compounds; Von Frey test; Hot plate test; Anti-Inflamatórios; Capacidade de absorbância de radicais de oxigênio; Flavonoides; Compostos fenólicos

Background: The aerial parts of Baccharis trimera (Less.) are frequently used as a tea to treat several diseases. Therefore, the aim of this study was to identify the constituents of an aqueous extract of B. trimera, focusing on their antioxidant, anti-inflammation, and antinociception activities and properties. For that, the researchers performed in vivo assays using the formalin test and Freund’s Complete Adjuvant (FCA) to measure the acute and chronic inflammatory pain in mice. Moreover, the myeloperoxidase enzyme (MPO) was analyzed in the subcutaneous tissue after the FCA injection, together with the counting of lymphocytes in the peripheral blood of the mice. Results: The qualitative phytochemical analysis indicated the presence of flavonoids and saponins in the B. trimera aqueous extract. The high-performance liquid chromatography (HPLC) analyses showed the presence of phenolic compounds, such as chlorogenic acid, ellagic acid, rosmarinic acid, as well as flavonoids, such as rutin, quercetin, and luteolin. The DPPH assay was used in order to measure the antioxidant activity of the aqueous extract of B. trimera and this showed an IC50 of 118.18 ± 1.02 μg/mg. The data from the formalin test demonstrated that a single dose of the aqueous extract of B. trimera was not able to decrease the nociceptive behavior during the neurogenic phase, at any of the tested doses (20, 40, or 80 mg/kg p.o.). However, during the inflammatory phase of this test, the aqueous extract of B. trimera at 80 mg/kg (p.o.) significantly decreased the nociceptive behavior, showing more effectiveness when compared to the other tested doses (p < 0.05). Importantly, in the chronic inflammatory model on the 5th day of treatment, the aqueous extract of B. trimera (80 mg/kg p.o.) significantly reduced mechanical allodynia (p < 0.01), heat thermal hyperalgesia (p < 0.001), and paw edema (p < 0.05). There were no changes in the MPO activity, but the data exhibited an equivalent decrease in the number of lymphocytes in the blood of the mice that were treated with B. trimera (80 mg.kg− 1 p.o.) and diclofenac sodium. Conclusion: Taken together, the present data reinforces the potential of the B. trimera aqueous extract as an antiinflammatory and analgesic compound.